stockrow
Friday 6 November 2026
Export TNDM’s income statement to Excel — free account
Tandem Diabetes Care, Inc.
TNDM Healthcare Medical Devices
Tandem Diabetes Care, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.93% from fiscal 2024.
- Revenue
- +13.8%
- EPS
- +67.7%
- Free cash flow
- −232.0%
- Total debt
- +94.9%
Quarter to September 2026, against a year earlier
16.78
1.21
−6.73%
Follow TNDM
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 5 | 3 |
+8 more TTM periods Free account |
| (36.74%) | (48.03%) | (65.73%) | (97.88%) | ||
| (4.84%) | (6.24%) | (9.11%) | (22.15%) | ||
ROIC |
(5.35%) | (10.33%) | (31.96%) | (67.83%) | |
Return on Tangible Assets |
(7.58%) | (9.95%) | (13.09%) | (44.60%) | |
Average Days of Receivables |
61.08 | 56.80 | 49.97 | 59.53 | |
Free Cash Flow per Share |
(0.52) | (0.39) | (0.05) | (0.44) | |
Free Cash Flow |
(36.30) | (26.62) | (3.64) | (29.67) | |
Capital Expenditures |
(21.69) | (21.09) | (23.25) | (19.95) | |
| Other line items | |||||
Cash ROIC |
(3.07%) | (2.24%) | (0.28%) | (3.91%) | |
Accounts Receivable Turnover |
7.03 | 7.17 | 7.69 | 7.25 | |
Accounts Payable Turnover |
7.63 | 7.64 | 7.74 | 10.21 | |
Inventory Turnover |
3.33 | 3.30 | 3.46 | 3.37 | |
Average Days of Payables |
58.54 | 51.10 | 47.18 | 36.65 | |
Days of Inventory on Hand |
112.00 | 107.65 | 99.62 | 100.27 | |
Tax Rate |
0.13 | 0.04 | (0.04) | 0.02 | |
Research and Development Expense of Revenue |
0.00% | 18.03% | 18.39% | 26.44% | |
Selling, General and Administrative Expense of Revenue |
41.54% | 42.38% | 42.76% | 43.85% | |
Share Based Compensation of Revenue |
6.27% | 6.98% | 8.03% | 9.10% | |
Interest Coverage |
(2.80) | (5.21) | (10.16) | (23.68) | |
Operating CF/Net income |
0.30 | 0.09 | (0.21) | 0.05 | |
Depreciation/Fixed assets |
0.00 | 0.19 | 0.20 | 0.19 | |
Capex/Depreciation |
0.00 | (1.29) | (1.42) | (1.27) | |
Revenue per Share |
15.45 | 15.09 | 15.02 | 15.08 | |
Operating CF per Share |
(0.21) | (0.08) | 0.29 | (0.14) | |
Capex per Share |
(0.31) | (0.31) | (0.34) | (0.30) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026